抗ディゴキシンファブ断片は,黄色いオレアンダーを摂取した心臓毒性:ランダム化制御試験
M Eddleston1, S Rajapakse, Rajakanthan
1Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, UK.
Lancet (London, England)
|April 18, 2000
まとめ
抗ディゴキシンファブ断片は,黄色いオレアンダーによって引き起こされる心律不整症を効果的に治療し,心拍数と心拍数を改善します. この治療は,患者の移送に対する安全な代替手段であり,スリランカの農村部での死亡率を潜在的に減らすことができます.
科学分野:
- 毒理学 毒理学 毒理学
- 心臓病学 心臓病学
- 薬理学 薬理学とは
背景:
- 黄色いオレーンダーシードを摂取すると,スリランカでは重度の心臓毒性が生じます.
- 現在の管理は,一時的な心臓ペースを保つために患者の移送を必要とします.
- ランダム化対照試験では,オレアンダー誘発性心律不整症に対する抗ディゴキシンFabを調査した.
研究 の 目的:
- 黄色いオレーンダーの摂取によって引き起こされる重度の心律異常を逆転させるための抗ディゴキシンFabの有効性を評価する.
- 田舎の保健医療施設での治療として,抗ディゴキシンファブの安全性と有効性を評価する.
主な方法:
- 66人の重篤な心律不整の患者を対象としたランダム化対照試験です.
- 患者は,抗ディゴキシンFabの1200mgまたは塩素プラセボを投与された.
- 心電図と血液サンプルを採取し,心拍数,電解質,グリコシド濃度をモニターした.
主要な成果:
- 抗ディゴキシンFabはプラセボより著しく早くリズムを緩和した (p<0.001).
- 抗体治療を受けた患者のより高い割合は,8時間以内に鼻腔リズムを達成した (p<0.001).
- 抗ディゴキシンFabによる治療は,心拍数増加と血清カリウム濃度の低下をもたらした.
結論:
- 抗ディゴキシンファブ断片は,黄色いオレアンダーによって引き起こされる心律不整症に対する安全で効果的な治療法です.
- この介入は,スリランカの農村部の病院における患者の移送と死亡率を潜在的に減らすことができます.
- 死亡率の減少を確認するためにさらなる研究が必要である.
関連する概念動画
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...


